Athira Pharma Q1 net loss narrows to $9.1M; ATH-1105 Phase 1 complete, ALS dosing on track

LeonaBio, Inc.

2025-Q1 EPS reported -$0.23

Cash, cash equivalents and investments totaled $36.7M as of March 31, 2025, down from $51.3M at year-end 2024.
Net loss for Q1 2025 was $9.1M ($0.23 per share) vs $26.3M ($0.69 per share) in Q1 2024.
R&D expenses fell to $4.3M from $21.2M, driven by fosgonimeton program cuts after failed LIFT-AD trial.
ATH-1105 Phase 1 healthy volunteer study completed; full data expected 2H25, ALS patient dosing to begin late 2025.
Company exploring strategic alternatives with Cantor Fitzgerald after discontinuing fosgonimeton development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.